Atezolizumab

Introduction

Atezolizumab is a monoclonal antibody used in immunotherapy for treating various cancers. It is designed to inhibit the programmed cell death ligand 1 (PD-L1) pathway, which plays a critical role in immune evasion by tumors. By blocking this pathway, Atezolizumab enhances the body's immune response against cancer cells.

Uses

Atezolizumab is used for the treatment of:

Non-Small Cell Lung Cancer (NSCLC): For patients with advanced or metastatic disease, particularly those with PD-L1 expression.
Bladder Cancer: For patients with locally advanced or metastatic urothelial carcinoma who have previously received chemotherapy.
Triple-Negative Breast Cancer: For patients with PD-L1-positive, locally advanced or metastatic disease.
Other Cancers: It is also being investigated for use in various other cancers, including certain types of head and neck cancers and hepatocellular carcinoma.

Brand Name	Atezolizumab
Type
Weight
Generic	Atezolizumab
Manufacturer
Available in	English বাংলা

Mechanism of Action

Atezolizumab works by binding to PD-L1, a protein found on the surface of cancer cells and immune cells. By blocking PD-L1 from interacting with its receptors (PD-1 and B7.1), Atezolizumab prevents the inhibition of T-cell activation and enhances the immune system's ability to recognize and destroy cancer cells.

How Long Does It Take to Work?

Patients may start to see clinical benefits from Atezolizumab after a few weeks of treatment, with some experiencing improvement in tumor response within 6 to 12 weeks. However, it may take several months for optimal results to become apparent.

Absorption

Atezolizumab is administered intravenously and has complete bioavailability through this route. The drug does not have a defined absorption phase as it is directly delivered into the bloodstream.

Route of Elimination

The elimination of Atezolizumab occurs primarily through the reticuloendothelial system. It is metabolized in the body, with degradation products eliminated via the feces and urine.

Dosage

General: Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either:

1200 mg administered by IV infusion every 3 weeks or
1680 mg administered by IV infusion every 4 weeks.

1L cisplatin-ineligible mUC: Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test

The typical dosage of Atezolizumab for adults is 1200 mg administered intravenously every 3 weeks. Dosage adjustments are generally not required, but treatment schedules may vary based on the type of cancer and patient response.

Administration

Atezolizumab is administered via intravenous infusion over a period of approximately 30 to 60 minutes. The infusion should be given by a healthcare provider experienced in the administration of intravenous medications.

Side Effects

Common side effects of Atezolizumab include:

Fatigue
Nausea
Fever
Rash
Diarrhea

Serious side effects may include immune-mediated adverse reactions affecting organs such as the lungs, liver, and endocrine glands. Prompt reporting and management of severe symptoms are essential.

Toxicity

Toxicity associated with Atezolizumab generally involves immune-mediated adverse effects. Overdose risk is minimal with intravenous administration, but severe immune reactions can occur. Management involves symptomatic treatment and, if necessary, corticosteroids to control immune-related side effects.

Precautions

Monitor patients for signs of immune-mediated adverse effects, including pneumonitis, hepatitis, adrenalitis, and thyroiditis. Caution is advised in patients with autoimmune conditions or prior immune-related adverse events.

Interaction

Atezolizumab has limited interactions with other drugs. However, it may affect the efficacy of certain medications due to its impact on the immune system. Inform your healthcare provider of all other medications you are taking.

Disease Interaction

Patients with a history of autoimmune diseases or active infection should use Atezolizumab with caution. The drug may exacerbate autoimmune conditions or increase susceptibility to infections.

Drug Interaction

There are no significant drug-drug interactions with Atezolizumab . However, its impact on the immune system may alter the effectiveness of other medications. Always inform your healthcare provider of all drugs you are using.

Food Interactions

There are no known food interactions with Atezolizumab . The drug can be administered regardless of food intake.

Pregnancy Use

The safety of Atezolizumab during pregnancy is not well established. It is classified as Category D (positive evidence of risk). It should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. Consult a healthcare provider if pregnant or planning to become pregnant.

Lactation Use

It is not known whether Atezolizumab is excreted in human breast milk. Caution is advised when using this medication while breastfeeding. Discuss with your healthcare provider whether to continue breastfeeding or discontinue the drug.

Acute Overdose

Acute overdose of Atezolizumab is unlikely due to its intravenous administration. However, in case of suspected overdose, monitor the patient closely for adverse reactions and provide symptomatic treatment as needed.

Contraindication

Atezolizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be avoided in patients with severe, uncontrolled immune-related adverse events from previous treatments.

Use Direction

Administer Atezolizumab as prescribed by your healthcare provider. Do not alter the dose or frequency of administration without consulting your healthcare provider. Ensure adherence to the treatment schedule for optimal outcomes.

Storage Conditions

Store Atezolizumab at 2°C to 8°C (36°F to 46°F). Protect from light and avoid freezing. Keep out of reach of children and use within the specified expiration date.